NEW YORK, June 01, 2022–(BUSINESS WIRE)–Flatiron HealthⓇ today announced the appointment of Javier Jimenez, MD, MPH, as Chief Medical Officer, effective June 1, 2022. In his new role, Dr. Jimenez will drive our vision for integrated evidence, leveraging new approaches for the generation of evidence in oncology thanks to the committed care of the Flatiron network and adapted scientific methods and tools. His clinical expertise and proven leadership, along with his extensive experience in real-world evidence, will continue to advance our scientific endeavors and a future where we accelerate R&D and achieve a more equitable and sustainable cancer care ecosystem. Dr. Jimenez succeeds Dr. Michael Vasconcelles, who will remain at Flatiron as Senior Advisor until August 1, 2022.
“Our commitment to reinventing the infrastructure of cancer care is unwavering. Mike has been instrumental in elevating and deepening the expertise and focus of our scientific, clinical and regulatory efforts, setting the building blocks of our path forward. I would like to thank Javier for his significant contributions to Flatiron, and for doing so with dedication and passion,” said Carolyn Starrett, CEO of Flatiron. “I am delighted to welcome Javier as a new medical director, joining our management team. Javier is a visionary and one of healthcare’s most experienced leaders in real-world evidence and novel study design. Flatiron is approaching our ten-year anniversary as a company, and we are more passionate than ever to lay the foundation for a world where cancer research and care is globally integrated and accelerated. Javier has pursued a similar vision as a Flatiron customer since our inception.
Prior to Flatiron, Dr. Jimenez served as Executive Vice President, Real World Evidence and Late Phase at Syneos Health, with expertise spanning clinical development, medical affairs, market access and product commercialization. While at Syneos Health, Dr. Jimenez developed the RWE function, integrating experts in RWE solutions, data and analytics, innovation and RWE clinical operations, while driving the RWD and analytics strategy and company technology. Dr. Jimenez began his journey in the pharmaceutical industry over twenty years ago, initially spending sixteen years leading teams in medical evidence, observational research, epidemiology, regulatory and HTA in the States. United States and Europe at AstraZeneca, while also building design and phase IIIb/IV delivery capabilities. Dr. Jimenez’s extensive experience in oncology includes leading AstraZeneca’s collaboration with ASCO’s CancerLinQ. Following his time at AstraZeneca, Dr. Jimenez spent four years developing the RWE, Advance Analytics and Clinical Outcomes functions at Sanofi to support all of Sanofi’s global business units, as well as developing technologies, tools and capabilities to leveraging RWD and generating insights. As a trained physician and epidemiologist, Dr. Jimenez is a passionate champion and key thought leader in using real-world data to transform regulatory decision-making and in the design of novel clinical trials. Dr. Jimenez’s recent research contributions cover predictive modeling of hypoglycemia in patients with type 2 diabetes and cardiovascular risk prevention, management in clinical practice settings, and the use of RWD to identify new indications for products in development and build research-grade RWD.
“I am extremely honored to join Flatiron, a global leader and pioneer in oncology evidence,” said Dr. Jimenez. “Flatiron is at a transformative point in its trajectory, working to create a more modern, connected oncology ecosystem – and I am inspired to be part of an organization that is committed to improving lives by learning from experience. of every cancer patient.”
About Flatiron Health
Flatiron Health is a health technology company dedicated to helping cancer centers thrive and provide better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy and advance research. Cancer is smart. Together we can be smarter. Flatiron Health is an independent subsidiary of the Roche Group. Flatiron.com @FlatironHealth
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220601005311/en/